Huonslab presents its remarkable formulation conversion technology at BIO USA

Proposing IV to SC conversion technology using human hyaluronidase

[Shin-Min Joon, Edaily Reporter] Huonslab of Huons Group introduced its formulation conversion technology using human hyaluronidase and innovative new drug candidates (pipelines) at the world’s largest biotechnology convention.

Huonslab participated in the BIO International Convention (BIO USA 2025) on June 16 (local time) in Boston, MA. Huonslab’s CBO, Dr. Byung Ha Lee, presented on the platform technology to convert IV infusion to SC injection and its pipelines. (Image=Huonslab)

Huonslab announced today that the company presented its HyDIFFUZE™ platform at the BIO International Convention 2025 (also known as BIO USA 2025) on June 16 local time in Boston, Massachusetts.

Hyaluronidase is an enzyme used as a drug dispersion agent by decomposing hyaluronic acid under human skin. Huonslab is currently advancing the development of platform technology that enables the conversion of intravenous (IV) antibody therapeutics into subcutaneous (SC) formulations using hyaluronidase.

HLB3-002 is manufactured with Huonlab’s process patent for HyDIFFUZETM manufacturing technology. This process method with high purity and high yield without fragmented byproducts provides enhanced dispersion efficacy. It is also known that HLB3-002, sharing an identical amino acid sequence with endogenous human hyaluronidase, offers a superior safety profiles.

Huonslab confirmed similar pharmacokinetics and drug dispersion efficacy as the original SC formulation through in vivo study using HyDIFFUZETM.

Huonslab also introduced its status on clinical trial. HLB3-002 is being developed as a stand-alone, proprietary alternative to Halozyme Therapeutics’ Hylenex®. HLB3-002 is currently undergoing pivotal phase 1 clinical trial in Korea and successfully completed the patient enrollment last month. Huonlab expects to submit a Biological License Application (BLA) for marketing approval with the MFDS by the second half of this year, pending trial outcomes.

A Chief Business Officer (CBO) of Huonslab Dr. Byung Ha Lee said “Presenting our HLB3-002 based technology at BIO USA reaffirmed possible technology transfer and collaboration with global pharmaceutical companies. Even when used alone, it has attracted great interest from many overseas companies due to its wide range of applications, including plastic surgery, beauty and aesthetics, and pain and swelling treatment.”

Huonslab plays a key role as a research and developing hub in Huons Group. Besides HLB3-002, Huonslab is developing pipelines for Alzheimer‘s disease, obesity and diabetes in pre clinical phases.

신민준 (adonis@edaily.co.kr)